Aethlon Medical receives European Patent Office notice of intent
Aethlon, known for developing selective therapeutic filtration devices, said that the EPO has provided it a notice of intent to issue a patent application entitled "Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis."
The Aethlon Hemopurifier, the company's best known filtration product, is currently used to capture broad-specturm infectious viral pathogens, including bioterror and pandemic threats, as well HIV and Hepatitis C.
"As we continue the successful expansion of our intellectual property portfolio, this patent will help to protect a substantial market opportunity for our Hemopurifier to address Hepatitis C and other infectious disease conditions throughout the European marketplace," Aethlon Medical Chairman and CEO Jim Joyce said.
The Hemopurifier is one part of the Aethlon ADAPT system, a range of filtration technologies that address infectious diseases and cancer. Aethlon is currently developing a new device under a contract with the U.S. Defense Advanced Research Projects Agency to reduce incidence of sepsis in soldiers and civilians injured in combat.